Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Icon ( (ICLR) ).
ICON plc said on February 12, 2026, that its audit committee is overseeing an internal investigation into revenue recognition and related controls for fiscal years 2023 through 2025, launched in late October 2025. Preliminary findings suggest 2023 and 2024 revenue may have been overstated by less than 2% per year, and the company expects to report one or more material weaknesses in internal controls over financial reporting.
As a result of the ongoing probe and associated delays to normal closing processes, ICON has withdrawn its full-year 2025 financial guidance and postponed its fourth-quarter and full-year 2025 earnings release to no later than April 30, 2026. The company said the issues under review have not affected customers and emphasized that management is implementing corrective actions to strengthen controls, while the board and executives seek to reassure stakeholders about governance and the underlying strength of the business.
The most recent analyst rating on (ICLR) stock is a Hold with a $183.00 price target. To see the full list of analyst forecasts on Icon stock, see the ICLR Stock Forecast page.
Spark’s Take on ICLR Stock
According to Spark, TipRanks’ AI Analyst, ICLR is a Outperform.
The score is driven primarily by solid financial strength (low leverage and strong revenue growth) but tempered by declining margins and weak TTM free cash flow growth. Technicals are supportive with price above major moving averages, while the earnings call was balanced—strong awards and cash generation offset by cancellations and pricing pressure. Valuation is reasonable but not distinctly cheap at a ~25.4 P/E.
To see Spark’s full report on ICLR stock, click here.
More about Icon
ICON plc is a world-leading clinical research organisation that supports pharmaceutical, biotechnology, medical device, government and public health clients worldwide. Headquartered in Dublin, Ireland, it provides integrated consulting, clinical development, commercialisation and post‑marketing services, employing about 40,100 staff across 97 locations in 55 countries as of December 31, 2025.
Average Trading Volume: 968,501
Technical Sentiment Signal: Strong Sell
Current Market Cap: $11.04B
Find detailed analytics on ICLR stock on TipRanks’ Stock Analysis page.